Maternal health and perinatal medicine are population health challenges which are in need of innovation. Preeclampsia and its sequela of eclampsia are among the most common reasons for maternal and perinatal morbidity, mortality and premature birth causing great human suffering and very high economic cost. Comanche is developing a novel treatment for preeclampsia with the goal of lowering the risks of poor birth outcomes, increasing the chances of the pregnancy reaching full term.
Location: United States, Massachusetts, Concord
Total raised: $75M
Investors 2
| Date | Name | Website |
| - | Population... | population... |
| - | F-Prime Ca... | fprimecapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.01.2024 | Series B | $75M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 17.01.2024 | Comanche secures $75M to test preeclampsia siRNA in PhII, ad... | - | fprimecapi... |
| 17.01.2024 | Comanche Biopharma Closes Oversubscribed $75 Million Series ... | - | globenewsw... |
| 28.10.2023 | The urgent call for innovation and investment in maternal he... | Maneesh Jain Contributor Share on X Maneesh Jain, PhD, is CEO and co-founder of Mirvie, a company ... | techcrunch... |
| 21.10.2022 | Explore how Breakthroughs in Biology are Improving Treatment... | JUPITER, Fla. (PRWEB) October 21, 2022 On an upcoming segment of Advancements with Ted Danson, audi... | prweb.com/... |
| - | Comanche Biopharma | “Comanche Biopharma” | fastfounde... |